Evolus, Inc.
EOLS
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $612.4M
$9.30
▲ +2.76%
P/E
-17.95
Mkt Cap
$612.4M
52-Wk Range
$3.86–$9.31
52-Week Range
$3.86 - $9.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary 900 kDa purified botulinum toxin formulation with differentiated manufacturing process
- Established distribution network among U.S. aesthetic practitioners and medical spas
- Focused product portfolio allowing specialized expertise and marketing efficiency in medical aesthetics
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Increasing consumer demand for non-invasive cosmetic procedures and aesthetic treatments
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+39.2% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EOLS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.01 vs -$0.03 consensus (+122.3% surprise). Revenue of $84.1M vs $81.5M expected (+3.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+122.3%
Revenue trend · last 8Q
—
+29%
+15%
+4%
+13%
+14%
+7%
+20%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$61.1M
$78.9M
$68.5M
$69.4M
$69.0M
$90.3M
$73.1M
$83.0M
Margins · last 8Q
Gross
70.8%
Operating
-5.5%
Profit
-9.7%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How EOLS stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related